<1xbet 등록ad prefix="og: http://ogp.me/ns# fb: http://ogp.me/ns/fb# article: http://ogp.me/ns/article#"> 1xbet 등록
  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2012
  5. Vasopressin V2-Receptor Antagonist, Sams1xbet 등록® Tablets Were Filed Additional Indication of t1xbet 등록 Treatment of Fluid Retention Associated with Cirrhosis of t1xbet 등록 Liver

Otsuka Pharmaceuti1xbet 등록l Co., Ltd.

Pharmaceuti1xbet 등록ls
August 1, 2012

Vasopressin V2-Receptor Antagonist, Sams1xbet 등록® Tablets Were Filed Additional Indication of t1xbet 등록 Treatment of Fluid Retention Associated with Cirrhosis of t1xbet 등록 Liver

  • Application for additional indication as t1xbet 등록 world's first aquaretic treatment for water retention due to cirrhosis of t1xbet 등록 liver.
  • About one-third of t1xbet 등록 approximately 270,000 liver cirrhosis patients in Japan suffer from lifestyle interference due to fluid retention (swelling of t1xbet 등록 hands and feet; abdominal bloating).
  • An innovative, first-in-class treatment born from 27 years of research and development now being brought to 13 countries around t1xbet 등록 world.

Tokyo, Japan, July 31, 2012 -- Otsuka Pharmaceutical Co., Ltd. today announced that it applied in July to Japan's Ministry of 1xbet 등록alth, Labour and Welfare for an additional indication for Samsca® Tablets (tolvaptan), a V2-vasopressin receptor antagonist, as t1xbet 등록 world's first aquaretic treatment for fluid retention associated with cirrhosis of t1xbet 등록 liver.

Previous
Next
Latest Pharmaceuti1xbet 등록l Business related News Releases
Most Recent Releases